Evaluation Of The Efficacy And Safety Of Anlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

Objective To explore and analyze the efficacy and safety of Anlotinib in the real world for advanced non-small cell lung cancer(NSCLC)third-line and above treatment.Methods Collect the data of 50 patients with advanced NSCLC who were treated with anlotinib in Lu’an People’s Hospital from 2018 to 2019.,and retrospectively analyze these data.Among them,45 patients received third-line treatment with anrotinib and 5patients received fourth-line treatment.Analysis and evaluation of the efficacy and safety of anlotinib and Kaplan-Meier for survival analysis.Results 47 patients received efficacy and survival analysis.There were no patients with complete remission.There were 2 patients(4.3%),24 patients(51.0%)and 21 patients(44.7%)who achieved partial remission,stable disease and progressed disease.The disease control rate(DCR)and objective response rate(ORR)were 55.3%,4.3%,respectively,the median progression-free survival(m PFS)and median overall survival(m OS)were 4.8 months(95% CI 2.904 ~ 6.696)and 8.6 months(95% CI5.853~11.347),respectively.The m OS and m PFS of elderly patients(≥60 years old)were 8.6 months(95% CI 5.853~11.347)and 5.8 months(95%CI 4.283~7.317).The adverse reactions that occurred with the use of anrotinib were basically tolerable,high incidence of adverse reactions were Anorexia(12.0%),hemoptysis(12.0%),abnormal liver function(8.0%),hand-foot syndrome(8.0%),hypertension(4.0%).Three patients discontinued medication due to intolerance of side effects,one case of hand-foot syndrome,one case of diarrhea,and one case of hematuria.Conclusion Elderly patients can also benefit from the use of anlotinib.The efficacy of using anlotinib in the third-line and above treatment of advanced non-small cell lung cancer in the real world is positive,and the use of anlotinib has fewer adverse reactions.